AMG 592

DRUG2 trials

Sponsors

Amgen

Conditions

Chronic Graft-versus-Host Disease (cGVHD)Chronic Graft-versus-host Disease (cGVHD)

Phase 1

A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants

CompletedNCT05873907

AmgenChronic Graft-versus-host Disease (cGVHD)

Start: 2015-10-19End: 2017-07-28Updated: 2023-05-24

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants

CompletedNCT05885451

AmgenChronic Graft-versus-Host Disease (cGVHD)

Start: 2019-01-29End: 2019-04-11Updated: 2023-06-02